Showing results (251-260 of 617) with videos related to
Sort By:
Pageof 62
Blood|October 2, 2004
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.American Journal of Hematology|September 28, 2010
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experienceHolbrook E Kohrt, Samit Patel, Michelle Ho, et al.Proceedings of the National Academy of Sciences of the United States of America|April 11, 2006
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationCatriona H M Jamieson, Jason Gotlib, Jeffrey A Durocher, et al.Archives of Dermatology|June 20, 2007
Imatinib as a treatment option for systemic non-Langerhans cell histiocytosesJochen Utikal, Selma Ugurel, Hjalmar Kurzen, et al.Cancer|March 29, 2019
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.American Journal of Hematology|May 7, 2016
Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remissionOfir Wolach, Kristen E Stevenson, Martha Wadleigh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2022
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for InterventionAndrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemiaGary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.Journal of the National Cancer Institute|March 22, 2024
Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemiaAndrew Hantel, Andrew M Brunner, Jesse J Plascak, et al.Pageof 62